TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04678102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHI-101 administration
Description: Escalated doses of PHI-101 will be administered to each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHI-101 administration
Description: Escalated doses of PHI-101 will be administered to each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHI-101 administration
Description: Escalated doses of PHI-101 will be administered to each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHI-101 administration
Description: Escalated doses of PHI-101 will be administered to each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHI-101 administration
Description: Escalated doses of PHI-101 will be administered to each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHI-101 administration
Description: Escalated doses of PHI-101 will be administered to each cohort.
Study: NCT01801254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIDES
Description: Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
Study: NCT02076841

Intervention type: DEVICE
Intervention: interferon beta-1a
Description: Administered as specified in the treatment arm
Study: NCT04883853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild _moderate Ptosis tucking
Description: A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
Study: NCT03257397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta-burst stimulation (TBS) using a MagPro X1000
Description: iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: theta-burst stimulation (TBS) using a MagPro X1000
Description: iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
Study: NCT00672009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
Study: NCT03830606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel,S-1
Description: Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
Study: NCT01155765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10 mg/day for 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150 mg/day for 15 days
Study: NCT00700765

Intervention type: DRUG
Intervention: insulin detemir
Description: For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
Study: NCT02502448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acute normovolemic hemodilution (ANH)
Description: applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch (HES 130/0.6)
Study: NCT03435419

Intervention type: DIAGNOSTIC_TEST
Intervention: LoopampTM Leishmania Detection Kit
Description: LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection

Intervention type: DIAGNOSTIC_TEST
Intervention: CL DetectTM Rapid Test
Description: CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
Study: NCT00645086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin extended-release tablets
Description: 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
Study: NCT01803542

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
Study: NCT01474187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: initial from 50mg/m2/week and increased by 15mg/m2/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m2,bid,d1-5,qw

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50Gy for whole pelvis
Study: NCT02522182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Intensive Secondary Prevention Programme
Description: Information related to intervention description have been already included in arm/group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment
Description: Information related to intervention description have been already included in arm/group description
Study: NCT03038139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical exercises
Description: Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumosacral exercises
Description: Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
Study: NCT03673358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT
Study: NCT01052415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sessions
Description: Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
Study: NCT01139879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P400 mattress
Description: The P400 mattress will be placed for a period of 12 weeks.
Study: NCT04498104

Intervention type: OTHER
Intervention: Psychological assessment
Description: Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.

Intervention type: OTHER
Intervention: Psychological assessment
Description: Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
Study: NCT04137536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR-bispecific antibody armed activated T-cells
Description: Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If \>/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)
Study: NCT00645086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin immediate-release tablets
Description: 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
Study: NCT00303043

Intervention type: PROCEDURE
Intervention: Mixed venous saturation monitoring
Description: Mixed venous saturation monitoring
Study: NCT00869297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Administration
Description: Intravenous Fluid will be given if SVV exceeds 13%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Fluids titrated at discretion of anesthesiologist.
Study: NCT03373019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with R-GDP
Description: Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
Study: NCT00634231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT03245879

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 1
Description: Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for \>48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 2
Description: Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 3
Description: Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
Study: NCT01743430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
Study: NCT05410990

Intervention type: DIAGNOSTIC_TEST
Intervention: eosinophil and other hematological parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: eosinophil and other hematological parameters
Study: NCT00596544

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Those women who have a FSFI score \> 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
Study: NCT03431610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB414 2%
Description: Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB414 6%
Description: Twice daily
Study: NCT01606878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT03407482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants received GDC-0853 at a dose of 200mg, as per the dosing schedule described above.
Study: NCT03431610

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo comparator
Study: NCT03052036

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary Angiography
Description: Coronary angiography to determine location of blocked or narrowed arteries.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary revascularisation
Description: PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.

Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Therapy
Description: Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.

Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Therapy
Description: Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
Study: NCT04143048

Intervention type: OTHER
Intervention: DNA extraction of tumer tissue samples and high-throughput sequencing of small panels
Description: DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed

Intervention type: OTHER
Intervention: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels
Description: DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor

Intervention type: OTHER
Intervention: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels
Description: DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
Study: NCT00627978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: ixabepilone 40 mg/m2 Q3w over 3 hours
Study: NCT01069939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg, capsule, 72 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsule, 72 weeks
Study: NCT01890993

Intervention type: DRUG
Intervention: liraglutide
Description: Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.

Intervention type: DRUG
Intervention: liraglutide
Description: Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
Study: NCT04359212

Intervention type: DRUG
Intervention: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
Description: thromboprophylaxis with low-molecular-weight heparin or fondaparinux

Intervention type: DRUG
Intervention: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
Description: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
Study: NCT02969278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18FDG-PET/TC
Description: Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Description: Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
Study: NCT04571632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab 5 MG/ML
Description: Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab 5 MG/ML
Description: Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size